Peptide natriuretico cerebrale quale biomarcatore di cardiotossicità in bambini affetti da malignità ematologiche.
Minerva Pediatr. 2012 Jun;64(3):307-12
Authors: Tragiannidis A, Dokos C, Tsotoulidou V, Giannopoulos A, Pana ZD, Papageorgiou T, Karamouzis M, Athanassiadou F
UNLABELLED: AIM Aim of our study was to evaluate BNP as early cardiotoxicity biomarker after completion of chemotherapy in twenty children with hematological malignancies at diagnosis (t=0) and after completion of intensive chemotherapy (t=1).
METHODS: Demographic data, underlying disease, cumulative anthracyclines dose, measurement of serum BNP and evaluation of systolic function of left ventricle with ejection fraction (EF) and shortening fraction (FS) in both times . Pathological values for EF and FS were found in 4 (20%) and 1 (5%) patient at t=1, while respective values were normal at diagnosis.
RESULTS: Mean BNP values at t=0 were 59.09±19.95 pg/mL and differ significantly from values at t=1 (153.22±29.14 pg/mL) (P=0.04). Mean value of EF also differed significantly (75.42±4.11% vs. 69.87±10.51%, P=0.04). No statistic difference was found regarding FS values at both (P=0.102).
CONCLUSION: Present data indicate that anthracyclines related cardiotoxicity is registered in children with hematological malignancies and BNP represents a useful biomarker of myocardial dysfunction.
PMID: 22555323 [PubMed - in process]